Analysts’ Viewpoint on Psoriasis Treatment Market Scenario
The global psoriasis treatment market is expected to grow at a rapid pace during the forecast period. Increase in adoption of personalized medicines for improved patient outcomes has encouraged market players to focus on newer modalities and biosimilars post the COVID-19 impact. The trend of tailor-made medicine for effective management of the disease is expected to drive the global psoriasis treatment market. Led by rapid medical advancements, players are focusing on leveraging the popularity of biologics for product innovation to meet the increasing demand in developed regional markets. Manufacturers should also consider strategic collaborations and acquisitions to broaden their product portfolio and strengthen their presence in the global landscape.
Rise in the psoriasis patient pool, approval of new biologic drugs for psoriasis, novel drug pipeline, and increase in access to psoriasis treatment in developing countries are anticipated to propel the global psoriasis treatment market.
Psoriasis is an autoimmune noncontagious disorder characterized by rapid and excessive proliferation of skin cells, resulting in patches of abnormal skin. Psoriasis is considered a long-term skin disorder characterized by plaques and thickened skin. Commonly affected areas on the body are around the scalp, knees, navel, and back of the forearms. Psoriasis is triggered by various factors, including environmental factors and genetic deformity. It is considered a non-curable disorder; however, a few treatments can ease the symptoms. Patients are likely to develop psoriatic arthritis at a faster rate. The number of patients with psoriatic arthritis has increased significantly over the last few years.
Biologics have altered the landscape in the management of moderate to severe psoriasis by achieving improved skin clearance, control of symptoms, and quality of life for many affected people. Usage of biologics in psoriasis treatment has resulted in lucrative prospects for manufacturers in the market, as they compete for the development of new products to stay competitive in the market.
In April 2019, Novartis AG announced that the China Health Authority NMPA approved Cosentyx (secukinumab), the first-in-class interleukin-17A (IL-17A) inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. This indicates promising potential of the plaque psoriasis treatment among patients.
Psoriasis diagnosis and treatment alternatives are undergoing a sea change in emerging economies. Awareness about psoriasis is increasing in developing countries such as China and India due to various campaigns by governments and healthcare professionals. It has become easy to access physicians or dermatologists for treatment in developing countries.
In November 2018, Novartis Corporation Malaysia launched ‘Be Pso Positive’, a psoriasis campaign in Malaysia. The campaign was created by Edelman Malaysia in association with the Psoriasis Association of Malaysia and True Complexion. This is expected to increase the number of patients treated for psoriasis, thereby augmenting the psoriasis treatment market during the forecast period.
In terms of drug class, the global psoriasis treatment market has been classified into TNF inhibitors, interleukin inhibitors, vitamin D analogs, corticosteroids, and others. The interleukin inhibitors segment is projected to dominate the global psoriasis treatment market during the forecast period. The segment's large market share can be attributed to the superior efficacy and safety of drugs in this class for the treatment of psoriasis. Rise in acceptance of this drug class is attributable to interleukin blockers, which are considered a viable option for patients who do not respond to other treatments.
Based on route of administration, the global psoriasis treatment market has been segregated into oral, parenteral, and topical. The parenteral segment accounted for the major share of the market in 2021. This trend is expected to continue during the forecast period. Growth of the segment can be ascribed to the increase in launch of new drugs to be administered through injection or intravenous (IV) infusion; and surge in the adoption of biologics for the treatment of psoriasis.
In terms of distribution channel, the global psoriasis treatment market has been divided into hospital pharmacies, retail pharmacies, and others. Retail pharmacies is projected to be a highly lucrative segment of the global market during the forecast period owing to higher sales of biologics in developed countries, including the U.S. and Canada.
North America dominated the global psoriasis treatment market in 2021 owing to the increase in incidence of psoriasis and favorable reimbursement policies in the region. Higher cost of biologics in North America than that in other regions is also likely to make it a primary market for players offering psoriasis treatment products. Additionally, robust product pipeline of key players is projected to boost the market in the region.
The psoriasis treatment market in Asia Pacific is anticipated to grow at a higher CAGR than that in North America during the forecast period due to the increase in awareness about psoriasis in developing countries of the region. Rise in diagnosis and management of psoriasis in healthcare systems & clinics in emerging economies is boosting the market in Asia Pacific. Furthermore, growth in usage of biologics in China and Japan is expected to augment the market in the region.
Recent advancements in psoriasis treatment is being witnessed in terms of new product approvals. In August 2021, Novartis secured a new approval for Cosentyx (secukinumab) for the treatment of pediatric moderate to severe plaque psoriasis in China.
The market in Latin America and Middle East & Africa is likely to grow at a considerable CAGR during the forecast period owing to the increase in psoriasis patient pool and focus of manufacturers on the development of novel therapeutics in these regions.
Manufacturers of psoriasis drugs are focusing on the launch of new products and are promoting their brands in order to increase market share. Psoriasis drug manufacturers emphasize on new marketing strategies to boost product penetration. Companies consider product approval and launch as a critical component of their growth strategy. They also concentrate on developing a value chain for major regional markets, as well as developing new psoriasis drugs and long-term solutions. Key players operating in the global psoriasis treatment market include Amgen, Inc., Eli Lilly and Company, Novartis AG, Merck & Co., Inc., Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, AbbVie, Inc., LEO Pharma A/S, and Biogen, Inc.
Each of these players has been profiled in the psoriasis treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 18.8 Bn |
|
Market Forecast Value in 2031 |
More than US$ 44 Bn |
|
Growth Rate (CAGR) |
8.7% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global psoriasis treatment market was valued at US$ 18.8 Bn in 2021.
The global market is projected to reach more than US$ 44 Bn by 2031.
The global psoriasis treatment market greew at a CAGR of 10.4% from 2017 to 2021.
The global psoriasis treatment market is anticipated to expand at a CAGR of 8.7% from 2022 to 2031.
Increase in number of psoriasis patients is augmenting the global psoriasis treatment market.
North America is expected to account for major share of the global psoriasis treatment market during the forecast period.
Prominent players in the global psoriasis treatment market include Amgen, Inc., Eli Lilly and Company, Novartis AG, Merck & Co., Inc., Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, AbbVie, Inc., LEO Pharma A/S, and Biogen, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Psoriasis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Psoriasis Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Regulatory Scenario by Region/Key Country
5.2. Pipeline Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Impact Analysis
6. Global Psoriasis Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. TNF Inhibitors
6.3.2. Interleukin Inhibitors
6.3.3. Vitamin D Analogs
6.3.4. Corticosteroids
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Psoriasis Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Topical
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Psoriasis Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Psoriasis Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Psoriasis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. TNF Inhibitors
10.2.2. Interleukin Inhibitors
10.2.3. Vitamin D Analogs
10.2.4. Corticosteroids
10.2.5. Others
10.3. Market Value Forecast, by Route of Administration, 2017–2031
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Topical
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Psoriasis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. TNF Inhibitors
11.2.2. Interleukin Inhibitors
11.2.3. Vitamin D Analogs
11.2.4. Corticosteroids
11.2.5. Others
11.3. Market Value Forecast, by Route of Administration, 2017–2031
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Topical
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Psoriasis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. TNF Inhibitors
12.2.2. Interleukin Inhibitors
12.2.3. Vitamin D Analogs
12.2.4. Corticosteroids
12.2.5. Others
12.3. Market Value Forecast, by Route of Administration, 2017–2031
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Topical
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Psoriasis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. TNF Inhibitors
13.2.2. Interleukin Inhibitors
13.2.3. Vitamin D Analogs
13.2.4. Corticosteroids
13.2.5. Others
13.3. Market Value Forecast, by Route of Administration, 2017–2031
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Topical
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. TNF Inhibitors
14.2.2. Interleukin Inhibitors
14.2.3. Vitamin D Analogs
14.2.4. Corticosteroids
14.2.5. Others
14.3. Market Value Forecast, by Route of Administration, 2017–2031
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Topical
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Amgen, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. AstraZeneca plc
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. AbbVie, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. Eli Lilly and Company
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. Johnson & Johnson
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Biogen, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. Novartis AG
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Merck & Co., Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Pfizer, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. LEO Pharma A/S
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Strategic Overview
15.3.11. Other Players
List of Table
Table 01: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 03: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Psoriasis Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 06: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 07: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 08: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 10: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 11: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 14: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 15: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 18: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 19: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 20: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 22: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 23: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 24: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Psoriasis Treatment Market Snapshot, 2021
Figure 02: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, 2017–2031
Figure 04: Global Psoriasis Treatment Market Value Share, by Route of Administration, 2021
Figure 06: Global Psoriasis Treatment Market Value Share, by Region, 2021
Figure 03: Global Psoriasis Treatment Market Value Share, by Drug Class, 2021
Figure 05: Global Psoriasis Treatment Market Value Share, by Distribution Channel, 2021
Figure 07: Regulatory Approval Process - U.S.
Figure 08: Regulatory Approval Process - Europe
Figure 09: Regulatory Approval Process - Japan
Figure 10: Global Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
Figure 11: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by TNF Inhibitors, 2017–2031
Figure 12: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Interleukin Inhibitors, 2017–2031
Figure 13: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vitamin D Analogs, 2017–2031
Figure 14: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2017–2031
Figure 15: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031
Figure 16: Global Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 17: Global Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
Figure 18: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017–2031
Figure 19: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parenteral, 2017–2031
Figure 20: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topical, 2017–2031
Figure 21: Global Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 22: Global Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
Figure 23: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2031
Figure 24: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2031
Figure 25: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031
Figure 26: Global Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 27: Global Psoriasis Treatment Market Value Share, by Region, 2021 and 2031
Figure 28: Global Psoriasis Treatment Market Attractiveness Analysis, by Region, 2022–2031
Figure 29: North America Psoriasis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 30: North America Psoriasis Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 31: North America Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
Figure 32: North America Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
Figure 33: North America Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
Figure 34: North America Psoriasis Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 35: North America Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 36: North America Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 37: North America Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 38: Europe Psoriasis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2031
Figure 39: Europe Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 40: Europe Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
Figure 41: Europe Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 42: Europe Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
Figure 43: Europe Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 44: Europe Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
Figure 45: Europe Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 46: Europe Psoriasis Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 47: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 48: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 49: Asia Pacific Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
Figure 50: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 51: Asia Pacific Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
Figure 52: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 53: Asia Pacific Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
Figure 54: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 55: Asia Pacific Psoriasis Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 56: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 57: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 58: Latin America Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
Figure 59: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 60: Latin America Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
Figure 61: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 62: Latin America Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
Figure 63: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 64: Latin America Psoriasis Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 65: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 66: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 67: Middle East & Africa Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
Figure 68: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 69: Middle East & Africa Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
Figure 70: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 71: Middle East & Africa Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
Figure 72: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 73: Middle East & Africa Market Value Share, by Country/Sub-region, 2021 and 2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Psoriasis Treatment Market
